This site is intended for healthcare professionals

Specialty hub

Neurology (CNS) and Pain

Containing dedicated Learning Zones, guidelines, trials and news for related conditions in Neurology (CNS) and Pain.

Read time: 5 mins

Last updated: 4th May 2022

Welcome:

Sign in/Register

Updates in your area
of interest

Articles your peers
are looking at

Bookmarks
saved

Days to your
next event

Neurology is the branch of medicine that deals with conditions and diseases involving the central nervous system (brain and spinal cord) and the peripheral nervous systems (autonomic and somatic), including their coverings, blood vessels, and all effector tissue such as muscle.

Learning Zones

Anticoagulation Therapy for Stroke Prevention

Learning Zone Homepage

Anticoagulation Therapy for Stroke Prevention

300 mins

Multiple Sclerosis (MS) Learning Zone

Multiple Sclerosis (MS) Learning Zone

250 mins

Innovations in MS care to improve individual disease management

Innovations in MS care to improve individual disease management

145 mins

Neurology encompasses over 5000 neurological diseases and relies on insights from fields such as neuroscience. This medical speciality deals with dementia including Alzheimer’s disease, Parkinson’s disease, neuromuscular disorders including spinal muscular atrophy and pain management as a sub-speciality.

Diseases in this section

Attention Deficit Hyperactivity Disorder (ADHD)

Containing relevant Learning Zones, guidelines, trials and news.

Dementia

Containing relevant Learning Zones, guidelines, trials and news.

Depression

Containing relevant Learning Zones, guidelines, trials and news.

Epilepsy

Containing relevant Learning Zones, guidelines, trials and news.

Herpes Zoster

Containing relevant Learning Zones, guidelines, trials and news.

Neuromuscular Disorders

Containing relevant Learning Zones, guidelines, trials and news.

Pain

Containing relevant Learning Zones, guidelines, trials and news.

Parkinson's Disease

Containing relevant Learning Zones, guidelines, trials and news.

Related news and insights

Athersys announces that its partner, Healios K.K., reported topline data from the TREASURE multistem ischemic stroke study.

Athersys, Inc. announced that its partner, Helios K.K. (Healios), has reported topline results for its Japan ischemic stroke study, TREASURE.

2 mins

FDA accepts for review an NDA for intranasal zavegepant for the acute treatment of migraine.

Biohaven Pharmaceutical Holding Company Ltd. announced that the FDA has filed and accepted for review a New Drug Application (NDA) for zavegepant nasal spray, the only small molecule calcitonin gene-related peptide (CGRP) receptor antagonist in an intranasal formulation, for the acute treatment of migraine in adults.

1 min

Positive data from phase III study of Vraylar for the adjunctive treatment of major depressive disorder.

AbbVie announced it will present positive data from a Phase III trial of cariprazine (Vraylar; 1.5 mg/day), Study 3111-301-001, for the adjunctive treatment of major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant therapy.

1 min

See all news

Related Drugs

Trazodone Hydrochloride 50mg Capsules

Trazodone Hydrochloride 50mg Capsules

1 mins

Trazodone hydrochloride 50 mg hard capsules

Trazodone hydrochloride 50 mg hard capsules

1 mins

Trazodone Hydrochloride 100mg Capsules

Trazodone Hydrochloride 100mg Capsules

1 mins

Trazodone hydrochloride 100 mg hard capsules

Trazodone hydrochloride 100 mg hard capsules

1 mins

Tramadol 50 mg/ml solution for injection/infusion

Tramadol 50 mg/ml solution for injection/infusion

1 mins

Tegretol Chewtabs 200 mg

Tegretol Chewtabs 200 mg

1 mins

Tegretol Chewtabs 100 mg

Tegretol Chewtabs 100 mg

1 mins

Pregabalin Dr. Reddys 75 mg Capsules, Hard

Pregabalin Dr. Reddys 75 mg Capsules, Hard

1 mins

Pregabalin Dr. Reddys 50 mg Capsules, Hard

Pregabalin Dr. Reddys 50 mg Capsules, Hard

1 mins

Pregabalin Dr. Reddys 300 mg Capsules, Hard

Pregabalin Dr. Reddys 300 mg Capsules, Hard

1 mins

Pregabalin Dr. Reddys 25 mg Capsules, Hard

Pregabalin Dr. Reddys 25 mg Capsules, Hard

1 mins

Pregabalin Dr. Reddys 225 mg Capsules, Hard

Pregabalin Dr. Reddys 225 mg Capsules, Hard

1 mins

Pregabalin Dr. Reddys 200 mg Capsules, Hard

Pregabalin Dr. Reddys 200 mg Capsules, Hard

1 mins

Pregabalin Dr. Reddys 150 mg Capsules, Hard

Pregabalin Dr. Reddys 150 mg Capsules, Hard

1 mins

Pregabalin Dr. Reddys 100 mg Capsules, Hard

Pregabalin Dr. Reddys 100 mg Capsules, Hard

1 mins

Related Journals

Metabolic Risk Factors and Cardiovascular Safety in Ketamine Use for Treatment Resistant Depression

Metabolic Risk Factors and Cardiovascular Safety in Ketamine Use for Treatment Resistant Depression

1 mins

Research Progress on Classical Traditional Chinese Medicine Jieyu Pills in the Treatment of Depression

Research Progress on Classical Traditional Chinese Medicine Jieyu Pills in the Treatment of Depression

1 mins

Vagus Nerve Stimulation For Treatment Resistant Depression: Case Series Of Six Patients - Retrospective Efficacy And Safety Observation After One Year Follow Up

Vagus Nerve Stimulation For Treatment Resistant Depression: Case Series Of Six Patients - Retrospective Efficacy And Safety Observation After One Year Follow Up

1 mins

Patient-reported depression severity and cognitive symptoms as determinants of functioning in patients with major depressive disorder: a secondary analysis of the 2-year prospective PERFORM study

Patient-reported depression severity and cognitive symptoms as determinants of functioning in patients with major depressive disorder: a secondary analysis of the 2-year prospective PERFORM study

1 mins

Genetic determinants of circulating VEGF levels in major depressive disorder and electroconvulsive therapy response

Genetic determinants of circulating VEGF levels in major depressive disorder and electroconvulsive therapy response

1 mins

Serum level of soluble interleukin 6 receptor is a useful biomarker for identification of treatment-resistant major depressive disorder

Serum level of soluble interleukin 6 receptor is a useful biomarker for identification of treatment-resistant major depressive disorder

1 mins

Efficacy and safety of tipepidine as adjunctive therapy in major depressive disorder: A randomized, double-blind, placebo-controlled clinical trial

Efficacy and safety of tipepidine as adjunctive therapy in major depressive disorder: A randomized, double-blind, placebo-controlled clinical trial

1 mins

Benefit-Risk Assessment of Esketamine Nasal Spray vs. Placebo in Treatment-Resistant Depression

Benefit-Risk Assessment of Esketamine Nasal Spray vs. Placebo in Treatment-Resistant Depression

1 mins

At baseline patients treated with esketamine have higher burden of disease than other patients with treatment resistant depression: Learnings from a population based study

At baseline patients treated with esketamine have higher burden of disease than other patients with treatment resistant depression: Learnings from a population based study

1 mins

Genetic comorbidity between major depression and cardio-metabolic traits, stratified by age at onset of major depression

Genetic comorbidity between major depression and cardio-metabolic traits, stratified by age at onset of major depression

1 mins

Related Guidelines

Monitoring for antidepressant-associated adverse events in the treatment of patients with major depressive disorder: An international consensus statement

These recommendations were designed to ensure safety for patients with major depressive disorder (MDD) and to aid monitoring and management of adverse effects during treatment with approved antidepressant medications. The recommendations aim to inform prescribers about both the risks associated with these treatments and approaches for mitigating such risks.

1 mins

Consensus paper of the WFSBP Task Force on Genetics: Genetics, epigenetics and gene expression markers of major depressive disorder and antidepressant response

Major depressive disorder (MDD) is a heritable disease with a heavy personal and socio-economic burden. Antidepressants of different classes are prescribed to treat MDD, but reliable and reproducible markers of efficacy are not available for clinical use.

1 min

Clinical guidelines for the management of treatment-resistant depression: French recommendations from experts, the French Association for Biological Psychiatry and Neuropsychopharmacology and the fondation FondaMental

Background: Clear guidance for successive antidepressant pharmacological treatments for non-responders in major depression is not well established.

1 min

See all guidelines

Related Clinical Trials

Minocycline as Adjunctive Treatment for Treatment Resistant Depression (MINDEP2)

Minocycline as Adjunctive Treatment for Treatment Resistant Depression (MINDEP2)

2 mins

The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression (P-TRD)

The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression (P-TRD)

1 mins

ELEKT-D: Electroconvulsive Therapy (ECT) vs. Ketamine in Patients With Treatment Resistant Depression (TRD) (ELEKT-D)

ELEKT-D: Electroconvulsive Therapy (ECT) vs. Ketamine in Patients With Treatment Resistant Depression (TRD) (ELEKT-D)

1 mins

Efficacy and Safety of MK-1942 When Added to Stable Antidepressant Therapy in Participants With Treatment-Resistant Depression (TRD) (MK-1942-006)

Efficacy and Safety of MK-1942 When Added to Stable Antidepressant Therapy in Participants With Treatment-Resistant Depression (TRD) (MK-1942-006)

1 mins

A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression (SUSTAIN-3)

A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression (SUSTAIN-3)

1 mins

A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression

A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression

1 mins

A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in Participants With Treatment Resistant Major Depressive D

A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in Participants With Treatment Resistant Major Depressive D

1 mins

A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression (TRANSFORM-3)

A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression (TRANSFORM-3)

2 mins

An Efficacy Study of Teriflunomide in Participants With Relapsing Multiple Sclerosis (TOWER)

An Efficacy Study of Teriflunomide in Participants With Relapsing Multiple Sclerosis (TOWER)

3 mins

Identification of a Biomarker Predictive of Evolution of Parkinson Disease (GLIAPARK)

Identification of a Biomarker Predictive of Evolution of Parkinson Disease (GLIAPARK)

3 mins

Efficacy and Safety of Ofatumumab Compared to Placebo in Patients With Relapsing Multiple Sclerosis Followed by Extended Treatment With Open-label Ofatumumab

Efficacy and Safety of Ofatumumab Compared to Placebo in Patients With Relapsing Multiple Sclerosis Followed by Extended Treatment With Open-label Ofatumumab

3 mins

Efficacy and Safety of GWP42003-P for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults (GWPCARE3)

Efficacy and Safety of GWP42003-P for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults (GWPCARE3)

4 mins

Related Events

Alzheimer’s Association International Conference (AAIC) 2022

Alzheimer’s Association International Conference (AAIC) 2022

1 mins

6th Edition of International Conference on Neurology and Brain Disorders (INBC 2022)

6th Edition of International Conference on Neurology and Brain Disorders (INBC 2022)

1 mins

International Conference on Neuro-Ophthalmology and Eye Disorders (ICNOED) 2022

International Conference on Neuro-Ophthalmology and Eye Disorders (ICNOED) 2022

1 mins

ECNP Congress 2022

ECNP Congress 2022

1 mins

EAN Congress 2022

EAN Congress 2022

1 mins

Your peers are looking at...

Polivy + R-CHP approved by European Commission for people with previously untreated diffuse large B-cell lymphoma.

Polivy + R-CHP approved by European Commission for people with previously untreated diffuse large B-cell lymphoma.

1 mins

$NICE (UK) recommends romosozumab to treat severe osteoporosis after menopause in people at risk of fracture.$

NICE (UK) recommends romosozumab to treat severe osteoporosis after menopause in people at risk of fracture.

1 mins

Athersys announces that its partner, Healios K.K., reported topline data from the TREASURE multistem ischemic stroke study.

Athersys announces that its partner, Healios K.K., reported topline data from the TREASURE multistem ischemic stroke study.

2 mins

Nirogacestat achieved primary and all key secondary endpoints in phase III DeFi Trial in adult patients with progressing desmoid tumors.

Nirogacestat achieved primary and all key secondary endpoints in phase III DeFi Trial in adult patients with progressing desmoid tumors.

1 mins

Positive phase III study with aprocitentan demonstrates significant antihypertensive efficacy in patients with resistant hypertension.

Positive phase III study with aprocitentan demonstrates significant antihypertensive efficacy in patients with resistant hypertension.

4 mins

New data support renal and cardiovascular benefits of Kerendia in patients with and without history of left ventricular hypertrophy and chronic kidney disease and type 2 diabetes.

New data support renal and cardiovascular benefits of Kerendia in patients with and without history of left ventricular hypertrophy and chronic kidney disease and type 2 diabetes.

1 mins

Two large Xarelto studies support effectiveness of dual pathway inhibition in patients with coronary artery disease and/or peripheral artery disease.

Two large Xarelto studies support effectiveness of dual pathway inhibition in patients with coronary artery disease and/or peripheral artery disease.

1 mins

Complete Response Letter for VP 102 for the treatment of molluscum contagiosum.

Complete Response Letter for VP 102 for the treatment of molluscum contagiosum.

1 mins

Fifty percent of patients with ulcerative colitis treated with mirikizumab achieved clinical remission at one year in Phase III LUCENT-2 study.

Fifty percent of patients with ulcerative colitis treated with mirikizumab achieved clinical remission at one year in Phase III LUCENT-2 study.

2 mins

Discover all webinars

Discover all webinars

1 mins